These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 1316069)

  • 1. Pharmacokinetics of lomefloxacin in patients with cirrhosis.
    Lebrec D; Gaudin C; Benhamou JP
    Am J Med; 1992 Apr; 92(4A):41S-44S. PubMed ID: 1316069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function.
    Nilsen OG; Saltvedt E; Walstad RA; Marstein S
    Am J Med; 1992 Apr; 92(4A):38S-40S. PubMed ID: 1316068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of lomefloxacin in renally compromised patients.
    Blum RA; Schultz RW; Schentag JJ
    Antimicrob Agents Chemother; 1990 Dec; 34(12):2364-8. PubMed ID: 2088191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function.
    Leroy A; Fillastre JP; Humbert G
    Antimicrob Agents Chemother; 1990 Jan; 34(1):17-20. PubMed ID: 2327756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple-dose pharmacokinetics of rufloxacin in patients with cirrhosis.
    Triger DR; Granai F; Woodcock J; Wise R; Imbimbo BP
    Hepatology; 1993 Oct; 18(4):847-52. PubMed ID: 8406358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of renal function on the pharmacokinetics of lomefloxacin compared with other fluoroquinolones.
    Blum RA
    Am J Med; 1992 Apr; 92(4A):18S-21S. PubMed ID: 1316065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of temafloxacin in patients with liver impairment.
    Granneman GR; Mahr G; Locke C; Nickel P; Kirch W; Fabian W; Kinzig M; Naber KG; Sörgel F
    Clin Pharmacokinet; 1992; 22 Suppl 1():24-32. PubMed ID: 1319868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and tolerance of lomefloxacin after sequentially increasing oral doses.
    Morrison PJ; Mant TG; Norman GT; Robinson J; Kunka RL
    Antimicrob Agents Chemother; 1988 Oct; 32(10):1503-7. PubMed ID: 3214495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steady-state pharmacokinetics and sputum penetration of lomefloxacin in patients with chronic obstructive pulmonary disease and acute respiratory tract infections.
    Kovarik JM; Hoepelman AI; Smit JM; Sips PA; Rozenberg-Arska M; Glerum JH; Verhoef J
    Antimicrob Agents Chemother; 1992 Nov; 36(11):2458-61. PubMed ID: 1336948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and safety of single oral doses of lomefloxacin.
    Morse IS
    Biopharm Drug Dispos; 1990; 11(6):543-51. PubMed ID: 2207304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction study of lomefloxacin and ciprofloxacin with omeprazole and comparative pharmacokinetics.
    Stuht H; Lode H; Koeppe P; Rost KL; Schaberg T
    Antimicrob Agents Chemother; 1995 May; 39(5):1045-9. PubMed ID: 7625786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of ranitidine on renal clearance of lomefloxacin.
    Sudoh T; Fujimura A; Harada K; Sunaga K; Ohmori M; Sakamoto K
    Eur J Clin Pharmacol; 1996; 51(1):95-8. PubMed ID: 8880059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lomefloxacin clinical pharmacokinetics.
    Freeman CD; Nicolau DP; Belliveau PP; Nightingale CH
    Clin Pharmacokinet; 1993 Jul; 25(1):6-19. PubMed ID: 8394795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal clearance of lomefloxacin is decreased by furosemide.
    Sudoh T; Fujimura A; Shiga T; Sasaki M; Harada K; Tateishi T; Ohashi K; Ebihara A
    Eur J Clin Pharmacol; 1994; 46(3):267-9. PubMed ID: 8070509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of multiple-dose oral lomefloxacin on theophylline metabolism in man.
    Wijnands GJ; Cornel JH; Martea M; Vree TB
    Chest; 1990 Dec; 98(6):1440-4. PubMed ID: 2245687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacokinetics of norfloxacin and lomefloxacin in aqueous humour analysed by microdialysis].
    Sato H; Fukuda S; Inatomi M; Koide R; Uchida N; Kanda Y; Kiuchi Y; Oguchi K
    Nippon Ganka Gakkai Zasshi; 1996 Jul; 100(7):513-9. PubMed ID: 8741334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lomefloxacin concentrations in bone after a single oral dose.
    On A; Nightingale CH; Quintiliani R; Sweeney KR; Pasternak HS; Maderazo EG
    Am J Med; 1992 Apr; 92(4A):15S-17S. PubMed ID: 1316064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and tissue penetration of orally administered lomefloxacin.
    Stone JW; Andrews JM; Ashby JP; Griggs D; Wise R
    Antimicrob Agents Chemother; 1988 Oct; 32(10):1508-10. PubMed ID: 3190181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Highperformance liquid chromatographic assay for lomefloxacin in plasma and its pharmacokinetics in healthy volunteers].
    Tan L; Xu DK; Diao Y; Yuan YS
    Yao Xue Xue Bao; 1993; 28(4):286-9. PubMed ID: 8213172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Lomefloxacin pharmacokinetics in patients in the terminal stage of chronic renal insufficiency, undergoing treatment with programmed hemodialysis].
    Kolendo SE; Vorob'ev PA; Dvoretskiĭ LI; Izotova GN; Miagkov AV; Shvyreva GS; Iakovlev SV
    Antibiot Khimioter; 1995 Mar; 40(3):47-51. PubMed ID: 7575015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.